Capricor Therapeutics Lawsuit Deadline for Investors September 28, 2026

Investors who have experienced significant losses in Capricor Therapeutics, Inc. (NASDAQ: CAPR) securities are now encouraged to take action. A securities fraud class action lawsuit has been filed against Capricor, with a lead plaintiff deadline set for September 28, 2026, for investors to submit their losses.

The lawsuit alleges that Capricor may have misled investors by providing false or misleading information regarding the company's business, product development, and financial condition. These alleged misrepresentations could have significantly impacted the company's stock price.

The law firm filing the lawsuit is seeking investors who have incurred losses to come forward for more information on the process and potential participation. The September 28, 2026, deadline is critical for investors wishing to assert their claims in the litigation.

Capricor Therapeutics is a biotechnology company focused on developing cell-based therapies for cardiovascular diseases. A decline in the value of the company's securities may have resulted from alleged omissions or misstatements presented in press releases or other public disclosures.

Further details regarding the lawsuit and its requirements are available through the law firm. Investors should carefully review the relevant documents and deadlines.